The gut's full report

The pancreas gets the credit and the brain gets the headlines, but the largest endocrine organ in the body is the one that never looks like a gland: the gut. Scattered through its lining are enteroendocrine cells, each a chemical sensor that tastes what you ate and answers in peptides. Together they outnumber every classical endocrine gland combined. After a meal, that lining files a report. It says what arrived, in what order, how far along digestion has run, and how hard the brain should push back on the next bite.

For a decade the world has been reading one line of that report very closely. GLP-1, released from the gut after eating, became the molecule behind the era’s defining metabolic drugs. But GLP-1 was never a soloist. It is one voice in a coordinated chorus, co-released with others, timed against the meal, and answered by the brain as a whole. What follows is a reference read of the rest of the report: the family of gut and appetite peptides the incretin era only partly borrowed.

The gut’s signals are not a single “full” alarm. They are sequenced, each tied to a stage of the meal. CCK goes first. Within minutes of fat and protein reaching the duodenum, I-cells release it, and it does three jobs at once: it contracts the gallbladder, triggers pancreatic enzyme secretion, and signals early satiety through the vagus nerve (Moran & Dailey, Int. J. Obes., 2009). CCK is the peptide that couples the arrival of food to the machinery that digests it.

Acid gets its own messenger. As the stomach’s contents turn the duodenum acidic, secretin is released from S-cells and calls for bicarbonate from the pancreas and bile ducts, neutralizing the acid and setting the pH that digestive enzymes need. Then, further along the intestine, the meal reaches the L-cells, and this is where the report’s most consequential lines are written. As nutrients arrive in the distal gut, L-cells release GLP-1 and PYY together, slowing everything upstream and reporting fullness. Physiologists call the effect the ileal brake: nutrients reaching the far intestine feed back to slow proximal transit and curb further eating (Maljaars et al., 2007).

One peptide runs on the opposite schedule. Motilin fires between meals, in the fasted state, pacing the migrating motor complex: the rhythmic housekeeping wave that sweeps residue through the gut once digestion is done. It is the report’s timekeeper rather than its satiety signal, and it is the reason an empty gut is not a quiet one.

Here is the fact the blockbuster era quietly rests on: GLP-1 and PYY come from the same cell. The intestinal L-cell co-secretes both after a meal, the incretin the drugs copied and a satiety peptide the drugs mostly left behind. They are released together but read differently. GLP-1 acts through its own class B receptor. Circulating PYY is trimmed by the same DPP-4 enzyme that degrades GLP-1 into its active PYY3-36 form, which acts at Y2 receptors on the appetite circuits of the hypothalamus, a different receptor on a different arm of the same system.

That difference is the whole point. When Batterham and colleagues infused PYY3-36 into people at levels the body reaches after a meal, it reduced food intake at the next meal by roughly a third, a genuine physiological satiety signal working independently of GLP-1 (Batterham et al., Nature, 2002). Two messages, one cell, two separate doors into satiety. The drug industry walked confidently through the GLP-1 door and, for years, left the PYY one mostly shut.

If the chorus theory needed a proof of concept, it already had one, and it came from the operating room rather than the lab. Bariatric surgery produces weight loss far beyond what mechanical restriction can explain, and the mechanism turned out to be largely hormonal. By rerouting or reshaping the gut, surgery delivers nutrients to the L-cell-rich distal intestine faster and in far greater quantity, and the post-meal chorus rises dramatically: GLP-1 and PYY together, several-fold, meal after meal (le Roux et al., Ann. Surg., 2006; 2007).

The elegant confirmation is the subtraction experiment: block those gut hormones after surgery and the appetite suppression eases. The weight loss that once looked purely mechanical is, in substantial part, the body running its own enteroendocrine report at a volume it never reaches on an ordinary plate. Surgery does not add a drug. It turns up the chorus.

So the real frontier is not “a better GLP-1.” It is adding the other voices back. The cleanest demonstration is a controlled infusion: give people GLP-1, oxyntomodulin and PYY together, the combination built to mimic the post-bypass hormone profile, and body weight and glycemia improve in a way modeled on surgery rather than on any one receptor (Behary et al., Diabetes Care, 2019). It is direct evidence that the combination, not any single hormone, is the lever.

The translational versions follow the same logic. Preclinical and early-clinical work pairs a GLP-1 agonist with a PYY3-36 analog under an explicit banner, a “medical gastric bypass,” aiming to reconstruct the two-peptide L-cell signal pharmacologically (Dischinger et al., 2020). It sits alongside the amylin story this reference has told before: pramlintide and cagrilintide reach satiety through the area postrema, a different door again, which is why amylin-plus-GLP-1 combinations stack rather than duplicate. Every one of these programs is the same move: restore a signal the gut sends for free that a single-agonist drug leaves out (see also the triple agonist and is there a GLP-4?).

The scepticism the page owes: none of this is a solved combination yet, and the gut’s report has resisted bottling for good reasons. PYY analogs have struggled with nausea and with the same short half-life that limited the native peptide. “Mimics bariatric surgery” is a mechanism claim, not an outcome guarantee, and the infusion studies are small and short. The honest statement is that the direction is well-founded, because the chorus is real, surgery proves it, and the biology says the voices should add, while the finished multi-peptide drugs are still being written.

The three peptides the drug frontier has mostly passed over are worth reading on their own, because each teaches something the GLP-1 story does not. CCK was the first gut peptide tied to meal-ending satiety, and on paper it looks like an appetite drug waiting to happen. It never became one: native CCK lasts only minutes, and sustained CCK-receptor stimulation runs into tachyphylaxis and gallbladder effects. Its lesson is the one the whole family keeps repeating, that a real satiety signal is not automatically a usable drug.

Secretin carries the field’s founding story. It was the first hormone ever discovered, the molecule that gave “hormone” its meaning when Bayliss and Starling showed in 1902 that a chemical messenger carried in the blood, not a nerve, drove the pancreas to answer duodenal acid. It also carries a cautionary one. In the late 1990s secretin became a sensation as a proposed autism treatment on the strength of a few anecdotes; when it was finally tested properly, a string of randomized, double-blind trials found no benefit at all (Sandler et al., NEJM, 1999; reviewed across fifteen controlled trials, 2005). The molecule was real, the mechanism was misapplied, and only the controlled test could tell the difference.

Motilin, finally, is the one that never touches satiety at all, and yet it is quietly the most “drugged” of the three, by accident. Certain macrolide antibiotics, erythromycin chief among them, happen to be motilin-receptor agonists, which is why a dose of erythromycin can jump-start a stalled stomach and why it is used off-label for gastroparesis (Kato et al., 2019; Sanger et al., 2014). The between-meal timekeeper turned out to carry a pharmacology no one designed.

Step back and the gut looks less like plumbing and more like a sensory organ that writes to the brain in a language of peptides. It reports on every meal, what arrived and how acidic and how far along, in a vocabulary the body coordinates in time. The incretin era’s achievement was to read one word of that language clearly enough to build a medicine on it. The next era’s ambition, visible in the surgery data and the combination programs, is to read the sentence.

• The gut is an endocrine organ, and it sends a timed report. CCK at the start of the meal, secretin for acid, GLP-1 and PYY from the distal L-cells for satiety and the ileal brake, motilin between meals. Appetite is answered by the whole sequence, not one signal.
• GLP-1 and PYY share a cell but not a receptor. The L-cell co-secretes both; the drugs copied GLP-1 and left PYY, which suppresses appetite through the independent Y2 pathway. A second, stackable door into satiety.
• Surgery is the proof that the chorus, not the solo, drives appetite. Gastric bypass raises the whole post-meal peptide profile several-fold, and blocking those hormones eases the effect. A single-agonist drug reproduces one line of what surgery performs in full.
• The frontier is rebuilding the report, not perfecting one peptide. GLP-1-plus-PYY 'medical bypass' pairs, tri-hormone GOP infusions, amylin stacks: each adds back a signal the gut sends for free. Well-founded in mechanism, not yet finished as medicine.
• A real satiety signal is not automatically a drug. CCK's short life and tachyphylaxis, PYY's nausea, secretin's famous null trials in autism. The family is a catalog of why the gut's own report is hard to bottle, and why the controlled test is the only arbiter.